Download PDF
Semin Thromb Hemost 2014; 40(03): 296-305
DOI: 10.1055/s-0034-1370767
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelet–Cancer Interactions

Hadi A. Goubran
1   Saskatoon Cancer Centre and Division of Oncology, Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Canada
,
Julie Stakiw
1   Saskatoon Cancer Centre and Division of Oncology, Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Canada
,
Mirjana Radosevic
2   Human Protein Process Sciences, Research and Development Department, Lille, France
,
Thierry Burnouf
3   Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
› Author Affiliations
Further Information

Publication History

Publication Date:
03 March 2014 (online)

    Permissions and Reprints

Abstract

Platelets play a crucial role in the pathophysiological processes of hemostasis and thrombosis. Increasing evidence indicates that they fulfill much broader roles in balancing health and disease. The presence of tumor cells affects platelets both numerically, through a wide variety of mediators and cytokines, or functionally through tumor cell–induced platelet activation, the first step toward cancer-induced thrombosis. This induction results from signaling events through the different platelet receptors, or may be cytokine-mediated. Reciprocally, upon activation, the platelets will release a myriad of growth factors from their dense and α-granules and peroxisomes; these will directly impact tumor growth, tethering, and spread. A similar cross-talk is initiated between tumor microvesicles stimulating the platelets and platelet microparticles, promoting both thrombosis and tumor growth. A vicious loop of activation thereafter takes place. Platelets directly and indirectly promote tumor growth, and enable a molecular mimicry coating the malignant growth and allowing metastasizing cells to escape T-cell–mediated immunity and natural killer cell surveillance. Breaking this vicious activation loop with nonspecific platelet inhibitors, such as aspirin, or by targeting specific sites on the activation cascade may offer a mean to reduce both the risks of development and progression of cancer and the risk of thrombosis.

Keywords

cancer - platelets - TCIPA - metastasis - antiplatelets - microparticles
 

  • References

  • 1 Smyth S, Whiteheart S, Italiano JE, Coller B. Platelet Morphophology, biochemistry and function. In: Kaushansky et al, eds. Williams Hematology. 8th ed. New York: McGraw–Hill; 2010: 1735
    Google Scholar
  • 2 Kurtz L, Kao L, Newman D, Kurtz I, Zhu Q. Integrin αIIbβ3 inside-out activation: an in situ conformational analysis reveals a new mechanism. J Biol Chem 2012; 287 (27) 23255-23265
    CrossrefPubMedGoogle Scholar
  • 3 Kato Y, Fujita N, Kunita A , et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003; 278 (51) 51599-51605
    CrossrefPubMedGoogle Scholar
  • 4 Suzuki-Inoue K, Inoue O, Ding G , et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010; 285 (32) 24494-24507
    CrossrefPubMedGoogle Scholar
  • 5 Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9 (4) 261-272
    CrossrefPubMedGoogle Scholar
  • 6 Geng JG, Chen M, Chou KC. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem 2004; 11 (16) 2153-2160
    CrossrefPubMedGoogle Scholar
  • 7 Jin R, Yu S, Song Z , et al. Soluble CD40 ligand stimulates CD40-dependent activation of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst. PLoS ONE 2013; 8 (6) e64631
    CrossrefPubMedGoogle Scholar
  • 8 Goubran HA, Burnouf T. Platelets, coagulation and cancer: multifaceted interactions. Am Med J 2012; 3 (2) 130-140
    CrossrefPubMedGoogle Scholar
  • 9 Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110 (6) 1723-1729
    CrossrefPubMedGoogle Scholar
  • 10 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (6) 715-722
    CrossrefPubMedGoogle Scholar
  • 11 Lima LG, Leal AC, Vargas G, Porto-Carreiro I, Monteiro RQ. Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb Res 2013; 132 (4) 450-456
    CrossrefPubMedGoogle Scholar
  • 12 Varon D, Shai E. Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 2009; 8 (43) 237-241
    PubMedGoogle Scholar
  • 13 Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013; 24 (5) 393-400
    CrossrefPubMedGoogle Scholar
  • 14 Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3 (7) 425-430
    CrossrefPubMedGoogle Scholar
  • 15 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (6) 585-593
    CrossrefPubMedGoogle Scholar
  • 16 Wu KK, Barnes RW, Hoak JC. Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation 1976; 53 (4) 687-691
    CrossrefPubMedGoogle Scholar
  • 17 Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30 (12) 2362-2367
    CrossrefPubMedGoogle Scholar
  • 18 Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974; 84 (5) 615-619
    PubMedGoogle Scholar
  • 19 Blay JY, Favrot M, Rossi JF, Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993; 82 (7) 2261-2262
    PubMedGoogle Scholar
  • 20 Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology (Am Soc Hematol Educ Program) 2007; 363-370
    PubMedGoogle Scholar
  • 21 Hwang SG, Kim KM, Cheong JH , et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012; 38 (7) 562-567
    CrossrefPubMedGoogle Scholar
  • 22 Göğüş C, Baltaci S, Filiz E, Elhan A, Bedük Y. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63 (3) 447-450
    CrossrefPubMedGoogle Scholar
  • 23 Ayhan A, Bozdag G, Taskiran C, Gultekin M, Yuce K, Kucukali T. The value of preoperative platelet count in the prediction of cervical involvement and poor prognostic variables in patients with endometrial carcinoma. Gynecol Oncol 2006; 103 (3) 902-905
    CrossrefPubMedGoogle Scholar
  • 24 Zhu JF, Cai L, Zhang XW , et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer 2014; 33 (2) 96-104
    CrossrefPubMedGoogle Scholar
  • 25 Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M , et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res 2012; 43 (4) 305-311
    CrossrefPubMedGoogle Scholar
  • 26 Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968; 61 (1) 46-52
    CrossrefPubMedGoogle Scholar
  • 27 Heinmöller E, Weinel RJ, Heidtmann HH , et al. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol 1996; 122 (12) 735-744
    CrossrefPubMedGoogle Scholar
  • 28 Heinmöller E, Schropp T, Kisker O, Simon B, Seitz R, Weinel RJ. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol 1995; 30 (10) 1008-1016
    CrossrefPubMedGoogle Scholar
  • 29 Boukerche H, Berthier-Vergnes O, Penin F , et al. Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol 1994; 87 (4) 763-772
    CrossrefPubMedGoogle Scholar
  • 30 Bastida E, Escolar G, Almirall L, Ordinas A. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost 1986; 55 (3) 333-337
    PubMedGoogle Scholar
  • 31 Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113 (3) 340-345
    CrossrefPubMedGoogle Scholar
  • 32 Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 2004; 141 (2) 241-252
    CrossrefPubMedGoogle Scholar
  • 33 Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012; 129 (Suppl. 01) S30-S37
    PubMedGoogle Scholar
  • 34 Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996; 10 (2) 457-484
    CrossrefPubMedGoogle Scholar
  • 35 Milsom C, Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb 2008; 36 (3-4) 160-176
    PubMedGoogle Scholar
  • 36 Lechner D, Weltermann A. Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?. Semin Thromb Hemost 2008; 34 (2) 199-203
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Wojtukiewicz MZ, Zacharski LR, Memoli VA , et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10 (3) 579-582
    PubMedGoogle Scholar
  • 38 Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993; 85 (15) 1225-1230
    CrossrefPubMedGoogle Scholar
  • 39 Wojtukiewicz MZ, Zacharski LR, Memoli VA , et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93 (4) 516-521
    PubMedGoogle Scholar
  • 40 Olas B, Mielicki WP, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelet adhesion. Thromb Res 1999; 94 (3) 199-203
    CrossrefPubMedGoogle Scholar
  • 41 Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331 (6024) 1559-1564
    CrossrefPubMedGoogle Scholar
  • 42 Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012; 72 (18) 4662-4671
    CrossrefPubMedGoogle Scholar
  • 43 Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006; 54 (2) 75-84
    CrossrefPubMedGoogle Scholar
  • 44 Tan BH, Fladvad T, Braun TP , et al; European Palliative Care Research Collaborative. P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med 2012; 4 (6) 462-471
    CrossrefPubMedGoogle Scholar
  • 45 Smyth SS, Woulfe DS, Weitz JI , et al; 2008 Platelet Colloquium Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 2009; 29 (4) 449-457
    CrossrefPubMedGoogle Scholar
  • 46 Lonsdorf AS, Krämer BF, Fahrleitner M , et al. Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. J Biol Chem 2012; 287 (3) 2168-2178
    CrossrefPubMedGoogle Scholar
  • 47 Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115 (17) 3427-3436
    CrossrefPubMedGoogle Scholar
  • 48 Chen YQ, Trikha M, Gao X , et al. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 1997; 72 (4) 642-648
    CrossrefPubMedGoogle Scholar
  • 49 Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008; 10 (8) 797-803
    PubMedGoogle Scholar
  • 50 Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 1995; 79 (3) 261-274
    CrossrefPubMedGoogle Scholar
  • 51 Kunita A, Kashima TG, Morishita Y , et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007; 170 (4) 1337-1347
    CrossrefPubMedGoogle Scholar
  • 52 Takagi S, Sato S, Oh-hara T , et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS ONE 2013; 8 (8) e73609
    CrossrefPubMedGoogle Scholar
  • 53 Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 2007; 97 (10) 1372-1380
    CrossrefPubMedGoogle Scholar
  • 54 Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32 (Suppl. 01) 61-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009; 29 (12) 1999-2004
    CrossrefPubMedGoogle Scholar
  • 56 Ekambaram P, Lambiv W, Cazzolli R, Ashton AW, Honn KV. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev 2011; 30 (3-4) 397-408
    CrossrefPubMedGoogle Scholar
  • 57 Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011; 10: 25
    CrossrefPubMedGoogle Scholar
  • 58 Vergote IB, van Dam PA, Laekeman GM, Keersmaeckers GH, Uyttenbroeck FL, Herman AG. Prostacyclin/thromboxane ratio in human breast cancer. Tumour Biol 1991; 12 (5) 261-266
    CrossrefPubMedGoogle Scholar
  • 59 Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998; 352 (9142) 1775-1777
    CrossrefPubMedGoogle Scholar
  • 60 Peterson JE, Zurakowski D, Italiano Jr JE , et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 85 (7) 487-493
    CrossrefPubMedGoogle Scholar
  • 61 Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 2010; 21 (2) 85-93
    CrossrefPubMedGoogle Scholar
  • 62 Laviano A, Rossi Fanelli F, Meguid MM. Serotonin and cancer anorexia: myths or facts?. J Clin Oncol 2005; 23 (9) 2111-2112 , author reply 2112 [author reply 2]
    CrossrefPubMedGoogle Scholar
  • 63 Alexander S, Stone P, White S, Andrews P, Nussey S, Bano G. Evaluation of central serotonin sensitivity in breast cancer survivors with cancer-related fatigue syndrome. J Pain Symptom Manage 2010; 40 (6) 892-898
    CrossrefPubMedGoogle Scholar
  • 64 Di Stefano JF, Kirchner M, Dagenhardt K, Hagag N. Activation of cancer cell proteases and cytotoxicity by EGF and PDGF growth factors. Am J Med Sci 1990; 300 (1) 9-15
    CrossrefPubMedGoogle Scholar
  • 65 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9 (1) 28-39
    CrossrefPubMedGoogle Scholar
  • 66 Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16 (5) 585-601
    CrossrefPubMedGoogle Scholar
  • 67 Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3 (1) 24-40
    CrossrefPubMedGoogle Scholar
  • 68 Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012; 31 (3-4) 553-568
    CrossrefPubMedGoogle Scholar
  • 69 Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012; 8 (7) 964-978
    CrossrefPubMedGoogle Scholar
  • 70 Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol 2013; 228 (4) 675-679
    CrossrefPubMedGoogle Scholar
  • 71 Kuhn DJ, Berkova Z, Jones RJ , et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012; 120 (16) 3260-3270
    CrossrefPubMedGoogle Scholar
  • 72 Zaslavsky A, Baek KH, Lynch RC , et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010; 115 (22) 4605-4613
    CrossrefPubMedGoogle Scholar
  • 73 Rollins BJ. Chemokines. Blood 1997; 90 (3) 909-928
    PubMedGoogle Scholar
  • 74 Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS ONE 2008; 3 (7) e2657
    CrossrefPubMedGoogle Scholar
  • 75 Ryo R, Proffitt RT, Poger ME, O'Bear R, Deuel TF. Platelet factor 4 antigen in megakaryocytes. Thromb Res 1980; 17 (5) 645-652
    CrossrefPubMedGoogle Scholar
  • 76 Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980; 19 (1-2) 129-137
    CrossrefPubMedGoogle Scholar
  • 77 Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys 1985; 240 (1) 446-455
    CrossrefPubMedGoogle Scholar
  • 78 Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83 (11) 3232-3239
    PubMedGoogle Scholar
  • 79 Amelot AA, Tagzirt M, Ducouret G, Kuen RL, Le Bonniec BF. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem 2007; 282 (1) 710-720
    CrossrefPubMedGoogle Scholar
  • 80 Cervi D, Yip TT, Bhattacharya N , et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111 (3) 1201-1207
    PubMedGoogle Scholar
  • 81 Wang Z, Huang H. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy. Cancer Lett 2013; 331 (2) 147-153
    CrossrefPubMedGoogle Scholar
  • 82 Borgström P, Discipio R, Maione TE. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res 1998; 18 (6A) 4035-4041
    PubMedGoogle Scholar
  • 83 van den Bosch H, de Vet EC, Zomer AW. The role of peroxisomes in ether lipid synthesis. Back to the roots of PAF. Adv Exp Med Biol 1996; 416: 33-40
    PubMedGoogle Scholar
  • 84 Onuchic AC, Machado CM, Saito RF, Rios FJ, Jancar S, Chammas R. Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma. Mediators Inflamm 2012; 2012: 175408
    PubMedGoogle Scholar
  • 85 Kim HA, Seo KH, Kang YR , et al. Mechanisms of platelet-activating factor-induced enhancement of VEGF expression. Cell Physiol Biochem 2011; 27 (1) 55-62
    PubMedGoogle Scholar
  • 86 Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009; 9 (4) 390-399
    CrossrefPubMedGoogle Scholar
  • 87 Chang CN, Feng MJ, Chen YL, Yuan RH, Jeng YM. p15(PAF) is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PLoS ONE 2013; 8 (4) e61196
    CrossrefPubMedGoogle Scholar
  • 88 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012; 38 (1) 102-113
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36 (8) 888-906
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Shai E, Rosa I, Parguiña AF, Motahedeh S, Varon D, García Á. Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. J Proteomics 2012; 76 (Spec No): 287-296
    CrossrefPubMedGoogle Scholar
  • 91 Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22 (1) 61-69
    CrossrefPubMedGoogle Scholar
  • 92 Varon D, Hayon Y, Dashevsky O, Shai E. Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thromb Res 2012; 130 (Suppl. 01) S98-S99
    CrossrefPubMedGoogle Scholar
  • 93 Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res 2012; 129 (Suppl. 01) S132-S136
    CrossrefPubMedGoogle Scholar
  • 94 Ronnlund D, Yang Y, Blom H, Auer G, Widengren J. Fluorescence nanoscopy of platelets resolves platelet-state specific storage, release and uptake of proteins, opening up future diagnostic applications. Adv Healthcare Mater 2012; 1 (6) 707-713
    CrossrefPubMedGoogle Scholar
  • 95 Amin C, Mackman N, Key NS. Microparticles and cancer. Pathophysiol Haemost Thromb 2008; 36 (3-4) 177-183
    PubMedGoogle Scholar
  • 96 Palumbo JS, Talmage KE, Massari JV , et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105 (1) 178-185
    CrossrefPubMedGoogle Scholar
  • 97 Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69 (19) 7775-7783
    CrossrefPubMedGoogle Scholar
  • 98 Lee YL, Lee LW, Su CY , et al. Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model. Transfusion 2013; 53 (9) 1918-1928
    CrossrefPubMedGoogle Scholar
  • 99 Placke T, Örgel M, Schaller M , et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res 2012; 72 (2) 440-448
    CrossrefPubMedGoogle Scholar
  • 100 Placke T, Kopp HG, Salih HR. The wolf in sheep's clothing: Platelet-derived “pseudo self” impairs cancer cell “missing self” recognition by NK cells. OncoImmunology 2012; 1 (4) 557-559
    CrossrefPubMedGoogle Scholar
  • 101 Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325 (23) 1593-1596
    CrossrefPubMedGoogle Scholar
  • 102 Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13 (5) 518-527
    CrossrefPubMedGoogle Scholar
  • 103 Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379 (9826) 1591-1601
    CrossrefPubMedGoogle Scholar
  • 104 Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med 2012; 125 (6) 560-567
    CrossrefPubMedGoogle Scholar
  • 105 Symeonidis D, Koukoulis G, Christodoulidis G, Mamaloudis I, Chatzinikolaou I, Tepetes K. Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastrointest Endosc 2012; 4 (9) 409-413
    CrossrefPubMedGoogle Scholar
  • 106 Cook NR, Lee IM, Gaziano JM , et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294 (1) 47-55
    CrossrefPubMedGoogle Scholar
  • 107 Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159 (2) 77-85
    CrossrefPubMedGoogle Scholar
  • 108 Serebruany VL. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. Fundam Clin Pharmacol 2009; 23 (4) 411-417
    CrossrefPubMedGoogle Scholar
  • 109 Serebruany VL, Dinicolantonio JJ, Can MM, Goto S. Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel. Cardiology 2013; 124 (2) 85-90
    CrossrefPubMedGoogle Scholar
  • 110 Kozlowski EO, Pavao MS, Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 2011; 9 (9) 1807-1815
    CrossrefPubMedGoogle Scholar
  • 111 Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5 (4) 729-737
    CrossrefPubMedGoogle Scholar
  • 112 Erdis E. Antiangiogenic behaviours of heparin derivatives may effect survival in lung cancer. Thromb Res 2013; 132 (3) e166
    CrossrefPubMedGoogle Scholar
  • 113 Asanuma K, Wakabayashi H, Okamoto T , et al. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer 2013; 20 (3) 241-246
    CrossrefPubMedGoogle Scholar
  • 114 Yang L, Du J, Hou J, Jiang H, Zou J. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer 2011; 11: 261
    CrossrefPubMedGoogle Scholar
  • 115 Lippi G, Favaloro EJ. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?. Semin Thromb Hemost 2010; 36 (5) 558-569
    Article in Thieme ConnectPubMedGoogle Scholar
  • 116 Hariri G, Zhang Y, Fu A , et al. Radiation-guided P-selectin antibody targeted to lung cancer. Ann Biomed Eng 2008; 36 (5) 821-830
    CrossrefPubMedGoogle Scholar